John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Fulcrum Therapeutics
FULC
$295M
| $400K | ﹤0.01% |
16,900
-504,090
| -97% | -$7.13M |
|
2102
Commault Systems
CVLT
$5.44B
| $399K | ﹤0.01% |
+6,017
| New | +$395K |
|
2103
Evergy
EVRG
$18.8B
| $398K | ﹤0.01% |
5,820
-34,327
| -86% | -$2.21M |
|
2104
Invitation Homes
INVH
$17.9B
| $398K | ﹤0.01% |
+9,895
| New | +$405K |
|
2105
Capital City Bank Group
CCBG
$875M
| $397K | ﹤0.01% |
15,078
+1,010
| +7% | +$27.6K |
|
|
RC
2106
Ready Capital
RC
$329M
| $397K | ﹤0.01% |
+26,372
| New | +$395K |
|
|
EPAY
2107
DELISTED
Bottomline Technologies Inc
EPAY
| $397K | ﹤0.01% |
6,997
-104,598
| -94% | -$5.91M |
|
|
OTRK
2108
DELISTED
Ontrak
OTRK
| $395K | ﹤0.01% |
1,939
+708
| +58% | +$193K |
|
2109
CorMedix
CRMD
$667M
| $394K | ﹤0.01% |
71,926
-32,934
| -31% | -$151K |
|
|
OTIC
2110
DELISTED
Otonomy, Inc.
OTIC
| $386K | ﹤0.01% |
160,696
-76,589
| -32% | -$163K |
|
|
AAT
2111
American Assets Trust
AAT
$1.42B
| $385K | ﹤0.01% |
10,155
-33,933
| -77% | -$1.24M |
|
2112
Cadiz
CDZI
$351M
| $385K | ﹤0.01% |
185,853
-51,348
| -22% | -$129K |
|
2113
Genpact
G
$6.26B
| $385K | ﹤0.01% |
8,855
-165,510
| -95% | -$7.67M |
|
2114
Regenxbio
RGNX
$588M
| $385K | ﹤0.01% |
+11,600
| New | +$322K |
|
2115
NN Inc
NNBR
$292M
| $384K | ﹤0.01% |
133,287
-9,726
| -7% | -$32K |
|
2116
Virtus Investment Partners
VRTS
$1.11B
| $384K | ﹤0.01% |
+1,600
| New | +$404K |
|
2117
Xeris Biopharma Holdings
XERS
$1.59B
| $384K | ﹤0.01% |
+150,109
| New | +$367K |
|
2118
Veru
VERU
$46.2M
| $383K | ﹤0.01% |
7,920
+6,862
| +649% | +$373K |
|
|
GRTX
2119
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $380K | ﹤0.01% |
+159,698
| New | +$416K |
|
|
VNET
2120
VNET Group
VNET
$1.96B
| $378K | ﹤0.01% |
64,754
-131,578
| -67% | -$1.01M |
|
|
FABC
2121
Fabric.AI Inc
FABC
$19M
| $375K | ﹤0.01% |
2,287
-2,195
| -49% | -$363K |
|
2122
Coursera
COUR
$1.64B
| $373K | ﹤0.01% |
16,200
-59,800
| -79% | -$1.23M |
|
|
PW
2123
Power REIT
PW
$2.83M
| $373K | ﹤0.01% |
+947
| New | +$540K |
|
|
RNLX
2124
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $373K | ﹤0.01% |
53,938
+6,031
| +13% | +$63.9K |
|
2125
Tenet Healthcare
THC
$21.9B
| $372K | ﹤0.01% |
4,330
+761
| +21% | +$62.5K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.